At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 164 enrolled
Drug / intervention
AZD5213 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Placebo-Controlled
In Brief
A Phase 2 clinical trial evaluating AZD5213 and Placebo for Mild Cognitive Impairment and Mild Alzheimer's Disease. Completed, enrolled 164 participants across 13 sites.
Detailed Summary
This is a study where AZD5213 or placebo is given to patients with Mild Alzheimer's Disease or Mild Cognitive Impairment in a blinded and random assignment. The main study objective is to estimate the relationship of sleep duration versus dose after 4 weeks of treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 2012
Enrollment StartApr 2012
Primary CompletionJan 2013
TodayJul 2026
First PostedMar 8, 2012
Enrollment StartApr 1, 2012
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 14.3 years ago
Interventions
AZD5213drug
AZD5213 doseA daily
AZD5213drug
AZD5213 doseB daily
AZD5213drug
AZD5213 doseC daily
Placeboother
Placebo tablet daily